Moderate/severe erectile dysfunction in patients with antiphospholipid syndrome

Area of Science:

• Reproductive Medicine
• Rheumatology
• Immunology

Background:

• Antiphospholipid syndrome (APS) is a rare autoimmune disorder associated with an increased risk of thrombosis.
• Sexual dysfunction, particularly erectile dysfunction (ED), can significantly impact the quality of life for patients with chronic diseases.

Purpose of the Study:

• To investigate the prevalence and characteristics of sexual dysfunction in male patients with antiphospholipid syndrome (APS).
• To compare sexual function between APS patients and healthy controls using the International Index of Erectile Function (IIEF).

Main Methods:

• A case-control study involving 11 male APS patients (Sapporo criteria) and 22 age- and race-matched healthy controls.
• Evaluation of demographic data, clinical history, medication use, and antiphospholipid antibodies.
• Self-administration of the Brazilian version of the validated International Index of Erectile Function (IIEF) questionnaire.

Main Results:

• Erectile dysfunction (ED) was significantly more prevalent in APS patients (45.5%) compared to controls (4.5%, p = 0.0096), with a higher incidence of moderate to severe ED (p = 0.0081).
• APS patients reported lower overall IIEF scores (p = 0.019), with significant reductions in erectile function (p = 0.005) and intercourse satisfaction (p = 0.009).
• In APS patients with ED, there was a higher occurrence of arterial thrombotic events (100% vs. 16.7%, p = 0.0152) and longer disease duration (12 vs. 5.5 years, p = 0.031).

Conclusions:

• This study demonstrates a high prevalence of moderate to severe erectile dysfunction in APS patients, suggesting a significant impact on sexual health.
• The findings link ED in APS to a history of arterial thrombotic events and prolonged disease duration.
• Further research is warranted to explore the underlying mechanisms and potential therapeutic strategies for ED in APS.